NCT05084261View on ClinicalTrials.gov

An Investigation of Oral BT051 in Subjects With Moderately to Severely Active Ulcerative Colitis (UC)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 30, 2021

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2022

Conditions
Ulcerative Colitis
Interventions
DRUG

BT051 200 mg

Oral BT051 200 mg once daily for 28 days.

DRUG

BT051 800 mg

Oral BT051 800 mg once daily for 28 days.

DRUG

BT051 3200 mg

Oral BT051 3200 mg once daily for 28 days.

DRUG

Matching Placebo

Placebo Matching BT051

Trial Locations (6)

34741

I.H.S. Health, LLC, Kissimmee

92377

Inland Empire Clinical Trials, LLC, Rialto

Unknown

Research Institute of Clinical Medicine Todua Clinic, Tbilisi

Republican Clinical Hospital - Timofei Mosneaga, Chisinau

WIP Warsaw IBD Point, Warsaw

PlanetMed Gastroenterology, Wroclaw

Sponsors

Lead Sponsor

Adiso Therapeutics
All Listed Sponsors
lead

Adiso Therapeutics

INDUSTRY

NCT05084261 - An Investigation of Oral BT051 in Subjects With Moderately to Severely Active Ulcerative Colitis (UC) | Biotech Hunter | Biotech Hunter